Valneva Submits Delisting Application to the Vienna Stock Exchange

  • Annual general meeting on June 27, 2019 resolved on the delisting of Valneva’s ordinary shares from the Vienna Stock Exchange
  • Delisting shall be effective by the end of 2019
  • Listing on Euronext Paris remains unchanged

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announces today that it has submitted a request to revoke the admission of its shares to the Vienna Stock Exchange (VSE). This decision was made by the Company in order to focus on the best capital markets for life science companies and increase liquidity by centralizing trading on Euronext Paris.

Read more